Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

Quantifying movement patterns and vaccination status of high risk mobile populations in Pakistan and Afghanistan to inform poliovirus risk and vaccination strategy.
Molodecky, NA; Usman, A; Javaid, A; Wahdan, A; PARKER, EP K; Ahmed, JA; Shah, N; Agbor, J; Mahamud, A; Safdar, RM;
2021
Vaccine, (2021).39 15 10.1016/j.vaccine.2021.03.001.
Hesitant or Not? The Association of Age, Gender, and Education with Potential Acceptance of a COVID-19 Vaccine: A Country-level Analysis.
Lazarus, JV; Wyka, K; Rauh, L; Rabin, K; Ratzan, S; Gostin, LO; LARSON, HJ; El-Mohandes, A;
2021
Journal of health communication, (2021).25 10 10.1080/10810730.2020.1868630.
Low immunogenicity of malaria pre-erythrocytic stages can be overcome by vaccination.
Müller, K; Gibbins, MP; Roberts, M; Reyes-Sandoval, A; Hill, AV S; Draper, SJ; Matuschewski, K; Silvie, O; HAFALLA, JC R;
2021
EMBO molecular medicine, (2021).13 4 10.15252/emmm.202013390.
Affordability of Adult Tuberculosis Vaccination in India and China: A Dynamic Transmission Model-Based Analysis.
WEERASURIYA, CK; Harris, RC; QUAIFE, M; MCQUAID, CF; WHITE, RG; Gomez, GB;
2021
Vaccines, (2021).9 3 10.3390/vaccines9030245.
Author Correction: Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA.
Loomba, S; De Figueiredo, A; Piatek, SJ; De Graaf, K; LARSON, HJ;
2021
Nature human behaviour, (2021).5 3 10.1038/s41562-021-01088-7.
Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.
Leach, AJ; MULHOLLAND, EK; Santosham, M; Torzillo, PJ; McIntyre, P; Smith-Vaughan, H; Wilson, N; Arrowsmith, B; Beissbarth, J; Chatfield, MD; Oguoma, VM; Morris, PS;
2021
BMC pediatrics, (2021).21 1 10.1186/s12887-021-02552-z.
Correcting COVID-19 vaccine misinformation: Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members.
Hotez, P; Batista, C; Ergonul, O; Figueroa, JP; Gilbert, S; Gursel, M; Hassanain, M; Kang, G; Kim, JH; Lall, B; LARSON, H; Naniche, D; Sheahan, T; Shoham, S; WILDER-SMITH, A; Strub-Wourgaft, N; Yadav, P; Bottazzi, ME;
2021
EClinicalMedicine, (2021).33, 10.1016/j.eclinm.2021.100780.
Immunological Considerations for Schistosoma Vaccine Development: Transitioning to Endemic Settings.
Driciru, E; Koopman, JP R; COSE, S; Siddiqui, AA; Yazdanbakhsh, M; ELLIOTT, AM; Roestenberg, M;
2021
Frontiers in immunology, (2021).12, 10.3389/fimmu.2021.635985.
Framework for Characterizing Longitudinal Antibody Response in Children After Plasmodium falciparum Infection.
Rogier, E; Nace, D; Dimbu, PR; Wakeman, B; Pohl, J; Beeson, JG; DRAKELEY, C; TETTEH, K; Plucinski, M;
2021
Frontiers in immunology, (2021).12, 10.3389/fimmu.2021.617951.
Human Papillomavirus Vaccination After COVID-19.
Toh, ZQ; Russell, FM; Garland, SM; MULHOLLAND, EK; Patton, G; Licciardi, PV;
2021
JNCI cancer spectrum, (2021).5 2 10.1093/jncics/pkab011.